Neuropeptide Y in noradrenergic neurons induces obesity in transgenic mouse models

Neuropeptides

Volumn 55, Issue , 2016, Pages 31-37

  Vähätalo, Laura H ^a   Ruohonen, Suvi T ^a   Ailanen, Liisa ^a   Savontaus, Eriika ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Endocannabinoid system; Glucose metabolism; Hepatosteatosis; Lipid metabolism; Metabolic disorder; Neuropeptide Y; Obesity

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR;

ADRENERGIC NERVE CELL; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; OBESITY; TRANSGENIC MOUSE;

ADRENERGIC NEURONS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE, TRANSGENIC; NEUROPEPTIDE Y; OBESITY; RECEPTORS, NEUROPEPTIDE Y;

EID: 84957917030     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2015.11.088     Document Type: Review

References (63)

1. Abe K., Kuo L., Zukowska Z. Neuropeptide Y is a mediator of chronic vascular and metabolic maladaptations to stress and hypernutrition. Exp. Biol. Med. (Maywood) 2010, 235:1179-1184.
2. Arbeeny C.M., Meyers D.S., Hillyer D.E., Bergquist K.E. Metabolic alterations associated with the antidiabetic effect of beta 3-adrenergic receptor agonists in obese mice. Am. J. Physiol. 1995, 268:E678-E684.
3. Cavadas C., Cefai D., Rosmaninho-Salgado J., Vieira-Coelho M.A., Moura E., Busso N., Pedrazzini T., Grand D., Rotman S., Waeber B., Aubert J.F., Grouzmann E. Deletion of the neuropeptide Y (NPY) Y1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10497-10502.
4. Chao P.T., Yang L., Aja S., Moran T.H., Bi S. Knockdown of NPY expression in the dorsomedial hypothalamus promotes development of brown adipocytes and prevents diet-induced obesity. Cell Metab. 2011, 13:573-583.
5. Chronwall B.M., DiMaggio D.A., Massari V.J., Pickel V.M., Ruggiero D.A., O'Donohue T.L. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 1985, 15:1159-1181.
6. Cox H.M. Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. Auton. Neurosci. 2007, 133:76-85.
7. D'Eon T.M., Pierce K.A., Roix J.J., Tyler A., Chen H., Teixeira S.R. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008, 57:1262-1268.
8. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
9. Ding B., Kull B., Liu Z., Mottagui-Tabar S., Thonberg H., Gu H.F., Brookes A.J., Grundemar L., Karlsson C., Hamsten A., Arner P., Ostenson C.G., Efendic S., Monne M., von Heijne G., Eriksson P., et al. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul. Pept. 2005, 127:45-53.
10. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Hakanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul. Pept. 1984, 8:225-235.
11. Everitt B.J., Hokfelt T., Terenius L., Tatemoto K., Mutt V., Goldstein M. Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. Neuroscience 1984, 11:443-462.
12. Fried G., Terenius L., Hokfelt T., Goldstein M. Evidence for differential localization of noradrenaline and neuropeptide Y in neuronal storage vesicles isolated from rat vas deferens. J. Neurosci. 1985, 5:450-458.
13. Fujimiya M., Inui A. Peptidergic regulation of gastrointestinal motility in rodents. Peptides 2000, 21:1565-1582.
14. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
15. Hohmann S., Buchmann A.F., Witt S.H., Rietschel M., Jennen-Steinmetz C., Schmidt M.H., Esser G., Banaschewski T., Laucht M. Increasing association between a neuropeptide Y promoter polymorphism and body mass index during the course of development. Pediatr. Obes. 2012, 7:453-460.
16. Jaakkola U., Pesonen U., Vainio-Jylhä E., Koulu M., Pöllönen M., Kallio J. The Leu7Pro polymorphism of neuropeptide Y is associated with younger age of onset of type 2 diabetes mellitus and increased risk for nephropathy in subjects with diabetic retinopathy. Exp. Clin. Endocrinol. Diabetes 2006, 114:147-152.
17. Jaakkola U., Kallio J., Heine R.J., Nijpels G., T'Hart L.M., Maassen J.A., Bouter L.M., Stehouwer C.D., Dekker J.M. Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study. Eur. J. Clin. Nutr. 2009, 63:150-152.
18. Jaakkola U., Kakko T., Seppalä H., Vainio-Jylhä E., Vahlberg T., Raitakari O.T., Kallio J. The Leu7Pro polymorphism of the signal peptide of neuropeptide Y (NPY) gene is associated with increased levels of inflammatory markers preceding vascular complications in patients with type 2 diabetes. Microvasc. Res. 2010, 80:433-439.
19. Kallio J., Pesonen U., Kaipio K., Karvonen M.K., Jaakkola U., Heinonen O.J., Uusitupa M.I., Koulu M. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J. 2001, 15:1242-1244.
20. Kallio J., Pesonen U., Jaakkola U., Karvonen M.K., Helenius H., Koulu M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J. Clin. Endocrinol. Metab. 2003, 88:3278-3283.
21. Karvonen M.K., Pesonen U., Koulu M., Niskanen L., Laakso M., Rissanen A., Dekker J.M., Hart L.M., Valve R., Uusitupa M.I. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat. Med. 1998, 4:1434-1437.
22. Kuo L.E., Kitlinska J.B., Tilan J.U., Li L., Baker S.B., Johnson M.D., Lee E.W., Burnett M.S., Fricke S.T., Kvetnansky R., Herzog H., Zukowska Z. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat. Med. 2007, 13:803-811.
23. Kuo L.E., Czarnecka M., Kitlinska J.B., Tilan J.U., Kvetnansky R., Zukowska Z. Chronic stress, combined with a high-fat/high-sugar diet, shifts sympathetic signaling toward neuropeptide Y and leads to obesity and the metabolic syndrome. Ann. N. Y. Acad. Sci. 2008, 1148:232-237.
24. Li A.J., Wang Q., Dinh T.T., Ritter S. Simultaneous silencing of Npy and Dbh expression in hindbrain A1/C1 catecholamine cells suppresses glucoprivic feeding. J. Neurosci. 2009, 29:280-287.
25. Liu J., Zhou L., Xiong K., Godlewski G., Mukhopadhyay B., Tam J., Yin S., Gao P., Shan X., Pickel J., Bataller R., O'Hare J., Scherer T., Buettner C., Kunos G. Hepatic cannabinoid receptor-mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012, 142:1218-1228.
26. Malenczyk K., Jazurek M., Keimpema E., Silvestri C., Janikiewicz J., Mackie K., Di Marzo V., Redowicz M.J., Harkany T., Dobrzyn A. CB1 cannabinoid receptors couple to focal adhesion kinase to control insulin release. J. Biol. Chem. 2013.
27. Masoudi-Kazemabad A., Jamialahmadi K., Moohebati M., Mojarrad M., Manshadi R.D., Akhlaghi S., Ferns G.A., Ghayour-Mobarhan M. Neuropeptide Y Leu7Pro polymorphism associated with the metabolic syndrome and its features in patients with coronary artery disease. Angiology 2013, 64:40-45.
28. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006, 91:3171-3180.
29. McDonald A.J., Pearson J.C. Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci. Lett. 1989, 100:53-58.
30. Mitchell G.C., Wang Q., Ramamoorthy P., Whim M.D. A common single nucleotide polymorphism alters the synthesis and secretion of neuropeptide Y. J. Neurosci. 2008, 28:14428-14434.
31. Niskanen L., Karvonen M.K., Valve R., Koulu M., Pesonen U., Mercuri M., Rauramaa R., Töyry J., Laakso M., Uusitupa M.I. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J. Clin. Endocrinol. Metab. 2000, 85:2266-2269.
32. Niskanen L., Voutilainen-Kaunisto R., Teräsvirta M., Karvonen M.K., Valve R., Pesonen U., Laakso M., Uusitupa M.I., Koulu M. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 2000, 108:235-236.
33. Nordman S., Ding B., Ostenson C.G., Karvestedt L., Brismar K., Efendic S., Gu H.F. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp. Clin. Endocrinol. Diabetes 2005, 113:282-287.
34. O'Hare J.D., Zielinski E., Cheng B., Scherer T., Buettner C. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes 2011, 60:1055-1062.
35. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 2005, 115:1298-1305.
36. Pihlajamäki J., Karhapää P., Vauhkonen I., Kekaläinen P., Kareinen A., Viitanen L., Pesonen U., Kallio J., Uusitupa M., Laakso M. The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism. Metabolism 2003, 52:643-646.
37. Poncelet M., Maruani J., Calassi R., Soubrie P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci. Lett. 2003, 343:216-218.
38. Potter E.K. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol. Ther. 1988, 37:251-273.
39. Renshaw D., Thomson L.M., Carroll M., Kapas S., Hinson J.P. Actions of neuropeptide Y on the rat adrenal cortex. Endocrinology 2000, 141:169-173.
40. Rucker D., Padwal R., Li S.K., Curioni C., Lau D.C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-1199.
41. Ruohonen S.T., Pesonen U., Moritz N., Kaipio K., Röyttä M., Koulu M., Savontaus E. Transgenic mice overexpressing neuropeptide Y in noradrenergic neurons: a novel model of increased adiposity and impaired glucose tolerance. Diabetes 2008, 57:1517-1525.
42. Ruohonen S.T., Abe K., Kero M., Toukola L., Ruohonen S., Röyttä M., Koulu M., Pesonen U., Zukowska Z., Savontaus E. Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury. Peptides 2009, 30:715-720.
43. Ruohonen S.T., Savontaus E., Rinne P., Rosmaninho-Salgado J., Cavadas C., Ruskoaho H., Koulu M., Pesonen U. Stress-induced hypertension and increased sympathetic activity in mice overexpressing neuropeptide Y in noradrenergic neurons. Neuroendocrinology 2009, 89:351-360.
44. Ruohonen S.T., Vähätalo L.H., Savontaus E. Diet-induced obesity in mice overexpressing neuropeptide y in noradrenergic neurons. Int. J. Pept. 2012, 2012:452524.
45. Sahu A., Kalra S.P., Crowley W.R., Kalra P.S. Evidence that NPY-containing neurons in the brainstem project into selected hypothalamic nuclei: implication in feeding behavior. Brain Res. 1988, 457:376-378.
46. Sawchenko P.E., Swanson L.W., Grzanna R., Howe P.R., Bloom S.R., Polak J.M. Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus. J. Comp. Neurol. 1985, 241:138-153.
47. Sell H., Deshaies Y., Richard D. The brown adipocyte: update on its metabolic role. Int. J. Biochem. Cell Biol. 2004, 36:2098-2104.
48. Shi Y.C., Lin S., Castillo L., Aljanova A., Enriquez R.F., Nguyen A.D., Baldock P.A., Zhang L., Bijker M.S., Macia L., Yulyaningsih E., Zhang H., Lau J., Sainsbury A., Herzog H. Peripheral-specific y2 receptor knockdown protects mice from high-fat diet-induced obesity. Obesity (Silver Spring) 2011, 19:2137-2148.
49. Shi Y.C., Lau J., Lin Z., Zhang H., Zhai L., Sperk G., Heilbronn R., Mietzsch M., Weger S., Huang X.F., Enriquez R.F., Baldock P.A., Zhang L., Sainsbury A., Herzog H., Lin S. Arcuate NPY controls sympathetic output and BAT function via a relay of tyrosine hydroxylase neurons in the PVN. Cell Metab. 2013, 17:236-248.
50. Steinman J.L., Gunion M.W., Morley J.E. Forebrain and hindbrain involvement of neuropeptide Y in ingestive behaviors of rats. Pharmacol. Biochem. Behav. 1994, 47:207-214.
51. Ukkola O., Kesäniemi Y.A. Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects. Eur. J. Clin. Nutr. 2007, 61:1102-1105.
52. Vähätalo L.H., Ruohonen S.T., Mäkelä S., Ailanen L., Penttinen A.M., Stormi T., Kauko T., Piscitelli F., Silvestri C., Savontaus E., Di Marzo V. Role of the endocannabinoid system in obesity induced by neuropeptide Y overexpression in noradrenergic neurons. Nutr. Diabetes 2015, 5.
53. Vähätalo L.H., Ruohonen S.T., Mäkelä S., Kovalainen M., Huotari A., Mäkelä K.A., Määttä J.A., Miinalainen I., Gilsbach R., Hein L., Ailanen L., Mattila M., Eerola K., Röyttä M., Ruohonen S., Herzig K.H., et al. Neuropeptide Y in the noradrenergic neurones induces obesity and inhibits sympathetic tone in mice. Acta Physiol. (Oxf.) 2015, 213:902-919.
54. Valet P., Berlan M., Beauville M., Crampes F., Montastruc J.L., Lafontan M. Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein. J. Clin. Invest. 1990, 85:291-295.
55. van Rossum C.T., Pijl H., Adan R.A., Hoebee B., Seidell J.C. Polymorphisms in the NPY and AGRP genes and body fatness in Dutch adults. Int. J. Obes. 2006, 30:1522-1528.
56. Varndell I.M., Polak J.M., Allen J.M., Terenghi G., Bloom S.R. Neuropeptide tyrosine (NPY) immunoreactivity in norepinephrine-containing cells and nerves of the mammalian adrenal gland. Endocrinology 1984, 114:1460-1462.
57. Wang Q., Wang M., Whim M.D. Neuropeptide y gates a stress-induced, long-lasting plasticity in the sympathetic nervous system. J. Neurosci. 2013, 33:12705-12717.
58. Yeung E.H., Zhang C., Chen J., Bowers K., Hu F.B., Kang G., Qi L. Polymorphisms in the neuropeptide Y gene and the risk of obesity: findings from two prospective cohorts. J. Clin. Endocrinol. Metab. 2011, 96:E2055-E2062.
59. Zain S.M., Mohamed Z., Jalaludin M.Y., Fauzi F., Hamidi A., Zaharan N.L. Comprehensive evaluation of the neuropeptide-gene variants in the risk of obesity: a case-control study and meta-analysis. Pharmacogenet. Genomics 2015, 25:501-510.
60. Zhang L., Lee N.J., Nguyen A.D., Enriquez R.F., Riepler S.J., Stehrer B., Yulyaningsih E., Lin S., Shi Y.C., Baldock P.A., Herzog H., Sainsbury A. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes. Metab. 2010, 12:591-603.
61. Zhang L., Macia L., Turner N., Enriquez R.F., Riepler S.J., Nguyen A.D., Lin S., Lee N.J., Shi Y.C., Yulyaningsih E., Slack K., Baldock P.A., Herzog H., Sainsbury A. Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. Int. J. Obes. 2010, 34:357-373.
62. Zhang L., Lee I.J., Enriquez R.F., Lau J., Vähätalo L.H., Baldock P.A., Savontaus E., Herzog H. Stress- and diet-induced fat gain is controlled by NPY in catecholaminergic neurons. Mol. Metab. 2014, 3:581-591.
63. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., Virkkunen M., Mash D.C., Lipsky R.H., Hu X.Z., Hodgkinson C.A., Xu K., Buzas B., Yuan Q., Shen P.H., Ferrell R.E., et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008, 452:997-1001.